Citi raised the firm’s price target on Zymeworks (ZYME) to $22 from $19 and keeps a Buy rating on the shares. The firm believes Zanidatamab is gaining traction in biliary tract cancer with the HERIZON data in late Q4 as the next catalyst for the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Reports Strong Q2 2025 Financial Performance
- Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
- Zymeworks reports Q2 EPS 3c, consensus (46c)
- Zymeworks Reports Q2 Results and FDA Clearance